MDK and neoplasm: Specifically, we set to test two clinically relevant aspects of the antitumoral activity of BO‐110: (i) organ‐dependent efficacies (namely, tumor vs lymph node and visceral sites), and (ii) the possibility of exploiting MDK as a biomarker of response in liquid biopsies (blood samples).